Efficacy and safety of cyclosporine and steroid for the treatment of minimal change nephrotic syndrome
Not Applicable
- Conditions
- Minimal change nephrotic syndrome
- Registration Number
- JPRN-UMIN000000963
- Lead Sponsor
- Yoshihiko Saito
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Cr>=2.0mg/dl or eGFR<50 Malignancy Uncontrolled hypertension Seizure disorder Pregnant women Infection Severe cardiac, hepatic or pancreatic disease Alelrgy to cyclosporine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate for complete remission Total dose of steroid Duration of admission
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cyclosporine's efficacy in minimal change nephrotic syndrome?
How does cyclosporine compare to standard-of-care steroids in MCNS treatment outcomes?
Which biomarkers correlate with response to cyclosporine in steroid-resistant MCNS patients?
What are the long-term adverse event profiles of cyclosporine-steroid combination therapy for MCNS?
Are there alternative immunosuppressive agents showing better safety profiles than cyclosporine in MCNS treatment?